Kodiak Sciences (KOD) Set to Post Earnings on Thursday

Kodiak Sciences (NASDAQ:KOD) is projected to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($1.06) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, analysts expect Kodiak Sciences to post ($3.97) EPS for the current fiscal year and ($4.14) EPS for the next fiscal year.

Kodiak Sciences Stock Performance

NASDAQ:KOD opened at $98.51 on Thursday. The stock has a market capitalization of $6.19 billion, a P/E ratio of -23.51 and a beta of 2.02. The company has a 50 day moving average price of $67.32 and a 200 day moving average price of $43.00. Kodiak Sciences has a fifty-two week low of $15.83 and a fifty-two week high of $104.00.

Insiders Place Their Bets

In other news, Director Bros. Advisors Lp Baker bought 33,726 shares of the stock in a transaction on Tuesday, September 29th. The shares were bought at an average price of $85.05 per share, with a total value of $2,868,396.30. Following the completion of the acquisition, the director owned 20,191,214 shares of the company’s stock, valued at approximately $1,717,262,750.70. This trade represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired a total of 1,941,755 shares of company stock valued at $156,986,026 over the last quarter. 44.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. HC Wainwright lifted their price objective on Kodiak Sciences from $96.00 to $126.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Lifesci Capital lifted their price objective on shares of Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a research report on Monday, September 28th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $112.00 price target on shares of Kodiak Sciences in a report on Monday, September 28th. Weiss Ratings cut Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 6th. Finally, JPMorgan Chase & Co. increased their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Kodiak Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $104.71.

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.